HUMANIGEN, INC: going-concern / distress — Humanigen files Chapter 11, agrees to sell assets to CEO-controlled Taran for up to $20M

HUMANIGEN, INC

Chapter 11 filed Jan 3 in Delaware; company will operate as debtor-in-possession, pursue court-supervised sale.
Enters asset purchase agreement with Taran Therapeutics (controlled by CEO Dr. Cameron Durrant) as stalking horse bidder for up to $20M ($2M cash + $18M milestones).
DIP loan of up to $2M from Taran to fund operations; cash at closing offset by DIP loan balance.
Common stock holders expected to experience complete or significant loss; trading is highly speculative.
Sale subject to Bankruptcy Court approval, competing bids, and other conditions; closing expected within ~70 days of petition.

item 1.01 item 1.03 item 2.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

HUMANIGEN, INC incurred credit facility of up to $2 million with Taran maturing five (5) months after the Petition Date.

Instrument: credit facility
Principal: up to $2 million
Counterparty: Taran
Maturity: five (5) months after the Petition Date
Event: incurrence

Exact text from the filing

Taran agreed to provide debtor in possession financing to the Company (the "DIP Loan"), pursuant to which, and subject to the satisfaction of the applicable conditions precedent contained therein, including the entry by the Bankruptcy Court of an appropriate order relating to the same (the "Interim DIP Order"), Taran would provide the Company with a DIP Loan in an aggregate principal amount of up to $2 million.

View on SEC.gov

Distress & Bankruptcy SEC 8-K Item 1.03 confidence 0.9

HUMANIGEN, INC entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2024-01-03).

Proceeding: chapter 11
Court: United States Bankruptcy Court for the District of Delaware
Petition: 2024-01-03

Exact text from the filing

On January 3, 2024 (the “Petition Date”), Humanigen, Inc. (the “Company”) filed a voluntary petition under chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). The Company’s chapter 11 case (the “Chapter 11 Case”) is being administered under the caption, In re Humanigen, Inc. , Case No. 24-10003 (BLS).

View on SEC.gov

283 debt financings filed in the last 30 days. Browse all debt financings →

Source: SEC EDGAR

accession 0001214659-24-000421

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.